Logo de TMX Newsfile
English

Matricelf Ltd.

Matricelf is a biotechnology company developing personalized regenerative therapies for spinal cord injury. Its investigational approach combines patient derived cells and biological material to create engineered neural tissue intended for transplantation into the injured spinal cord.

Nouvelles récentes

Matricelf Reports Statistically Significant Motor Function Improvement in Preclinical Efficacy Study of Chronic Spinal Cord Injury

Ness Ziona, Israel--(Newsfile Corp. - November 5, 2026) - Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized engineered neural tissue for spinal cord injury, today announced positive results from its comprehensive preclinical efficacy study, demonstrating statistically significant improvements in motor function following transplantation of its engineered human neural tissue. The tr

2026-11-05 11:31 AM EST

Prêt à annoncer en toute confiance?

Envoyez-nous un message, et un membre de notre équipe TMX Newsfile communiquera avec vous pour discuter de vos besoins.

Communiquez avec nous